Osteoclastogenic Potential of Peripheral Blood Mononuclear Cells in Cleidocranial Dysplasia
Open Access
- 1 January 2014
- journal article
- Published by Ivyspring International Publisher in International Journal of Medical Sciences
- Vol. 11 (4) , 356-364
Abstract
Cleidocranial dysplasia (CCD) is an autosomal dominant skeletal dysplasia characterized by hypoplastic or aplastic clavicles, dental abnormalities, and delayed closure of the cranial sutures. In addition, mid-face hypoplasia, short stature, skeletal anomalies and osteoporosis are common. We aimed to evaluate osteoclastogenesis in a child (4 years old), who presented with clinical signs of CCD and who have been diagnosed as affected by deletion of RUNX2, master gene in osteoblast differentiation, but also affecting T cell development and indirectly osteoclastogenesis. The results of this study may help to understand whether in this disease is present an alteration in the bone-resorptive cells, the osteoclasts (OCs). Unfractionated and T cell-depleted Peripheral Blood Mononuclear Cells (PBMCs) from patient were cultured in presence/absence of recombinant human M-CSF and RANKL. At the end of the culture period, OCs only developed following the addition of M-CSF and RANKL. Moreover, real-time PCR experiment showed that freshly isolated T cells expressed the osteoclastogenic cytokines (RANKL and TNFα) at very low level, as in controls. This is in accordance with results arising from flow cytometry experiments demonstrating an high percentage of circulating CD4+CD28+ and CD4+CD27+ T cells, not able to produce osteoclastogenic cytokines. Also RANKL, OPG and CTX serum levels in CCD patient are similar to controls, whereas QUS measurements showed an osteoporotic status (BTT-Z score -3.09) in the patient. In conclusions, our findings suggest that the heterozygous deletion of RUNX2 in this CCD patient did not alter the osteoclastogenic potential of PBMCs in vitro.Keywords
This publication has 38 references indexed in Scilit:
- Osteoclast Activated FoxP3+ CD8+ T-Cells Suppress Bone Resorption in vitroPLOS ONE, 2012
- Runx2-Upregulated Receptor Activator of Nuclear Factor κB Ligand in Calcifying Smooth Muscle Cells Promotes Migration and Osteoclastic Differentiation of MacrophagesArteriosclerosis, Thrombosis, and Vascular Biology, 2011
- CD16 (FcRγIII) as a potential marker of osteoclast precursors in psoriatic arthritisArthritis Research & Therapy, 2010
- The Role of Periodontal Ligament Cells in Delayed Tooth Eruption in Patients with Cleidocranial Dysostosis*Journal of Orofacial Orthopedics / Fortschritte der Kieferorthopädie, 2009
- Post-translational Regulation of Runx2 in Bone and CartilageJournal of Dental Research, 2009
- Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patientsLeukemia, 2009
- Osteoclastogenesis in Children with 21-Hydroxylase Deficiency on Long-Term Glucocorticoid Therapy: The Role of Receptor Activator of Nuclear Factor-κB Ligand/Osteoprotegerin ImbalanceThe Journal of Clinical Endocrinology & Metabolism, 2009
- Quantitative Ultrasound in the Management of Osteoporosis: The 2007 ISCD Official PositionsJournal of Clinical Densitometry, 2008
- Cross-sectional reference data for phalangeal quantitative ultrasound from early childhood to young-adulthood according to gender, age, skeletal growth, and pubertal developmentBone, 2006
- CD27+ memory and CD27- effector CD8+ T cells are responsible for a decreased production of proinflammatory cytokines in HLA B27-positive subjects.2006